Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
SBLOF Quote, Financials, Valuation and Earnings
Last price:
$10.03
Seasonality move
:
0%
Day range:
$10.03 - $10.03
52-week range:
$9.36 - $12.57
Dividend yield:
3.39%
P/E ratio:
13.55x
P/S ratio:
1.80x
P/B ratio:
1.63x
Volume:
--
Avg. volume:
7
1-year change:
2.14%
Market cap:
$417.6M
Revenue:
$212.6M
EPS (TTM):
$0.74
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Shin Nippon Biomedical Laboratories, Ltd. has -- downside to fair value with a price target of -- per share.
SBLOF vs. S&P 500
-
Over the past 5 trading days, Shin Nippon Biomedical Laboratories, Ltd. has underperformed the S&P 500 by -1.38% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Shin Nippon Biomedical Laboratories, Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Shin Nippon Biomedical Laboratories, Ltd. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Shin Nippon Biomedical Laboratories, Ltd. reported revenues of $56.2M.
Earnings Growth
-
Shin Nippon Biomedical Laboratories, Ltd. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Shin Nippon Biomedical Laboratories, Ltd. reported earnings per share of $0.13.
Enterprise value:
599.8M
EV / Invested capital:
1.16x
Price / LTM sales:
1.80x
EV / EBIT:
31.00x
EV / Revenue:
2.59x
PEG ratio (5yr expected):
0.77x
EV / Free cash flow:
-79.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
15.11x
Gross Profit (TTM):
$114.2M
Return On Assets:
4.91%
Net Income Margin (TTM):
13.12%
Return On Equity:
11.53%
Return On Invested Capital:
6.02%
Operating Margin:
4.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $192.7M | $180.5M | $231.7M | $46.6M | $56.2M | |
| Gross Profit | $101.2M | $96.3M | $114.2M | $23.4M | $24.5M | |
| Operating Income | $38.1M | $12.8M | $19.4M | $1.5M | $2.6M | |
| EBITDA | $50.4M | $27M | $39.7M | $5.7M | $8.2M | |
| Diluted EPS | $0.80 | $0.63 | $0.74 | $0.19 | $0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $125.3M | $167M | $199.7M | $237.4M | $212.5M | |
| Total Assets | $329.7M | $393.1M | $459.4M | $622.1M | $616M | |
| Current Liabilities | $98.9M | $127.7M | $149.5M | $201.5M | $192.7M | |
| Total Liabilities | $167.8M | $220.2M | $246.8M | $367.2M | $357.2M | |
| Total Equity | $161.9M | $172.9M | $212.6M | $254.9M | $258.8M | |
| Total Debt | $95.3M | $92.3M | $95.4M | $161M | $161.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-03-31 | 2010-03-31 | 2011-03-31 | 2010-03-31 | 2011-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $18.8M | $3.6M | $6.7M | $5.1M | |
| Cash From Investing | -- | -$23.4M | -$9.9M | -$7M | -$1.4M | |
| Cash From Financing | -- | $19.8M | -$4M | -$13.2M | -$23M | |
| Free Cash Flow | -- | -$4.5M | -$7.6M | $957.7K | $3.4M | |
SBLOF
Sector
Market Cap
$417.6M
$28.2M
Price % of 52-Week High
79.78%
50.25%
Dividend Yield
3.39%
0%
Shareholder Yield
1.08%
-1.54%
1-Year Price Total Return
2.14%
-18.1%
Beta (5-Year)
--
0.516
Dividend yield:
3.39%
Annualized payout:
$0.34
Payout ratio:
104%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$10.03
200-day SMA
Buy
Level
$9.46
Bollinger Bands (100)
Buy
Level
9.11 - 9.91
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$10.12
Relative Strength Index (RSI14)
Buy
Level
53.99
ADX Line
Neutral
Level
Williams %R
Buy
Level
-100
50-day SMA
Buy
Level
$9.67
MACD (12, 26)
Buy
Level
2.74
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4796)
Sell
CA Score
(Annual)
Level (-0.4378)
Buy
Beneish M-Score
(Annual)
Level (-2.4417)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.936)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: CRO Business, Translational Research Business, Medipolis Business, and Others. he CRO business is a business that verifies the efficacy and safety of test substances created by clients such as pharmaceutical companies using laboratory animals, cells, and bacteria. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.
Stock Forecast FAQ
In the current month, SBLOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBLOF average analyst price target in the past 3 months is --.
-
Where Will Shin Nippon Biomedical Laboratories, Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Shin Nippon Biomedical Laboratories, Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Shin Nippon Biomedical Laboratories, Ltd.?
Analysts are divided on their view about Shin Nippon Biomedical Laboratories, Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Shin Nippon Biomedical Laboratories, Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Shin Nippon Biomedical Laboratories, Ltd.'s Price Target?
The price target for Shin Nippon Biomedical Laboratories, Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBLOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Shin Nippon Biomedical Laboratories, Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SBLOF?
You can purchase shares of Shin Nippon Biomedical Laboratories, Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Shin Nippon Biomedical Laboratories, Ltd. shares.
-
What Is The Shin Nippon Biomedical Laboratories, Ltd. Share Price Today?
Shin Nippon Biomedical Laboratories, Ltd. was last trading at $10.03 per share. This represents the most recent stock quote for Shin Nippon Biomedical Laboratories, Ltd.. Yesterday, Shin Nippon Biomedical Laboratories, Ltd. closed at $10.03 per share.
-
How To Buy Shin Nippon Biomedical Laboratories, Ltd. Stock Online?
In order to purchase Shin Nippon Biomedical Laboratories, Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SBLOF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SBLOF
Sector
P/E ratio
13.55x
23.92x
PEG ratio
0.77x
-0.01x
P/B ratio
1.63x
1.83x
Price / LTM sales
1.80x
1.61x
Growth Metrics
SBLOF
Sector
Revenue growth
20.54%
4.6%
Earnings growth
-32.99%
10.88%
Revenue (5-year growth)
9.69%
6.46%
Earnings forecast
--
-$0.21
Profitability
SBLOF
Sector
Profitability FY 2024
$108.7M
$3.5M
Return on invested capital
6.02%
-31.84%
Return on assets
4.91%
-27.96%
Return on equity
11.53%
-37.63%
Earnings Date
Last Earnings Date
Dec
29
Next Earnings Date
Dec
29
Estimated Next Earnings Date
Mar
30
Balance Sheet
SBLOF
Sector
Total cash
$78.3M
$26.3M
Short term investments
$2.2M
$25.7M
Total assets
$618M
$76.9M
Long term debt
$161.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
